BACKGROUND: In Europe, a continuous programme (SPREAD) has been in place for ten years to study transmission of drug resistant HIV. We analysed time trends of transmitted drug resistance mutations (TDRM) in relation to the risk behaviour reported. METHODS: HIV-1 patients newly diagnosed in 27 countries from 2002 through 2007 were included. Inclusion was representative for risk group and geographical distribution in the participating countries in Europe. Trends over time were calculated by logistic regression. RESULTS: From the 4317 patients included, the majority was men-having-sex-with-men -MSM (2084, 48%), followed by heterosexuals (1501, 35%) and injection drug users (IDU) (355, 8%). MSM were more often from Western Europe origin, infected with subtype B virus, and recently infected (<1 year) (p<0.001). The prevalence of TDRM was highest in MSM (prevalence of 11.1%), followed by heterosexuals (6.6%) and IDU (5.1%, p<0.001). TDRM was predominantly ascribed to nucleoside reverse transcriptase inhibitors (NRTI) with a prevalence of 6.6% in MSM, 3.3% in heterosexuals and 2.0% in IDU (p = 0.001). A significant increase in resistance to non- nucleoside reverse transcriptase inhibitors (NNRTIs) and a decrease in resistance to protease inhibitors was observed in MSM (p = 0.008 and p = 0.006, respectively), but not in heterosexual patients (p = 0.68 and p = 0.14, respectively). CONCLUSIONS: MSM showed to have significantly higher TDRM prevalence compared to heterosexuals and IDU. The increasing NNRTI resistance in MSM is likely to negatively influence the therapy response of first-line therapy, as most include NNRTI drugs.

• MeSH
• dospělí MeSH
• heterosexualita statistika a číselné údaje   MeSH
• HIV infekce farmakoterapie   epidemiologie   přenos   virologie   MeSH
• HIV-1 účinky léků   MeSH
• homosexualita mužská statistika a číselné údaje   MeSH
• inhibitory proteas terapeutické užití   MeSH
• inhibitory reverzní transkriptasy terapeutické užití   MeSH
• intravenózní abúzus drog epidemiologie   virologie   MeSH
• látky proti HIV terapeutické užití   MeSH
• lidé středního věku MeSH
• lidé MeSH
• logistické modely MeSH
• riskování * MeSH
• riziko MeSH
• sexuální chování statistika a číselné údaje   MeSH
• virová léková rezistence * MeSH
• Check Tag
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH
• Geografické názvy
• Evropa epidemiologie   MeSH
• Názvy látek
• inhibitory proteas MeSH
• inhibitory reverzní transkriptasy MeSH
• látky proti HIV MeSH